NasdaqCM:PIRS

Stock Analysis Report

Executive Summary

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Pieris Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PIRS has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

5.9%

PIRS

0.7%

US Biotechs

-1.1%

US Market


1 Year Return

30.4%

PIRS

12.6%

US Biotechs

17.8%

US Market

Return vs Industry: PIRS exceeded the US Biotechs industry which returned 14% over the past year.

Return vs Market: PIRS exceeded the US Market which returned 17.9% over the past year.


Shareholder returns

PIRSIndustryMarket
7 Day5.9%0.7%-1.1%
30 Day22.3%5.9%1.5%
90 Day1.8%6.1%6.6%
1 Year30.4%30.4%13.5%12.6%20.2%17.8%
3 Year95.5%95.5%21.9%18.7%47.5%38.1%
5 Year21.5%21.5%2.9%-1.8%71.2%52.4%

Price Volatility Vs. Market

How volatile is Pieris Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pieris Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

9.45x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PIRS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PIRS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PIRS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PIRS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PIRS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PIRS is overvalued based on its PB Ratio (9.5x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Pieris Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-4.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PIRS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PIRS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PIRS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PIRS's revenue (26.6% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: PIRS's revenue (26.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PIRS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Pieris Pharmaceuticals performed over the past 5 years?

-20.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PIRS is currently unprofitable.

Growing Profit Margin: PIRS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PIRS is unprofitable, and losses have increased over the past 5 years at a rate of -20.5% per year.

Accelerating Growth: Unable to compare PIRS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PIRS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).


Return on Equity

High ROE: PIRS has a negative Return on Equity (-176.24%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Pieris Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: PIRS's short term assets ($98.0M) exceed its short term liabilities ($39.8M).

Long Term Liabilities: PIRS's short term assets ($98.0M) exceed its long term liabilities ($56.3M).


Debt to Equity History and Analysis

Debt Level: PIRS is debt free.

Reducing Debt: PIRS currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: PIRS has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if PIRS's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PIRS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PIRS has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of -3.2% each year.


Next Steps

Dividend

What is Pieris Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate PIRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PIRS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PIRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PIRS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PIRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Steve Yoder (43yo)

5.2yrs

Tenure

US$2,621,008

Compensation

Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as  ...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD2.62M) is above average for companies of similar size in the US market ($USD1.11M).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Stephen Yoder
CEO, President & Director5.2yrsUS$2.62m0.011% $23.7k
Thomas Bures
Principal Financial & Accounting Officer and Treasurer0.4yrsno data0.0093% $20.2k
Ahmed Mousa
Senior VP of Corporate Operations0yrsno datano data
Hitto Kaufmann
Senior VP & Chief Scientific Officer0.5yrsno datano data
Maria Kelman
Director of Investor Relations0yrsno datano data
Frank Vollmering
Vice President of Human Resources2.1yrsno datano data
Christine Rothe
Head of Discovery & Alliance Management and VP0yrsno datano data
Shane Olwill
Senior VP & Head of Translational Science0yrsno datano data
Eckhard Niemeier
Senior VP & Head of Business Development0yrsno datano data
Ingmar Bruns
Senior VP & Head of Clinical Development0yrsno datano data

1.3yrs

Average Tenure

Experienced Management: PIRS's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Stephen Yoder
CEO, President & Director5.2yrsUS$2.62m0.011% $23.7k
James Geraghty
Chairman2.2yrsUS$199.86k0.036% $79.0k
Michael Richman
Independent Director5.2yrsUS$144.40kno data
Christopher Kiritsy
Independent Director3.4yrsUS$152.76k0.018% $39.5k
Peter Kiener
Independent Director1.4yrsUS$105.52kno data
Matthew Sherman
Independent Director1.3yrsUS$99.96kno data
Ann Barbier
Independent Director1.8yrsUS$154.03kno data
Jean-Pierre Bizzari
Independent Director4.8yrsUS$139.95kno data
Maya Said
Director0.5yrsno datano data

2.2yrs

Average Tenure

58yo

Average Age

Experienced Board: PIRS's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Pieris Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pieris Pharmaceuticals, Inc.
  • Ticker: PIRS
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$217.154m
  • Shares outstanding: 54.98m
  • Website: https://www.pieris.com

Number of Employees


Location

  • Pieris Pharmaceuticals, Inc.
  • 255 State Street
  • 9th Floor
  • Boston
  • Massachusetts
  • 2109
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PIRSNasdaqCM (Nasdaq Capital Market)YesNew Common StockUSUSDDec 2014
PI6DB (Deutsche Boerse AG)YesNew Common StockDEEURDec 2014

Biography

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company is also developing PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., and Sanofi, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a research collaboration with the University of Pittsburgh. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 02:24
End of Day Share Price2020/02/21 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.